Giving the two immunotherapies ipilimumab and nivolumab simultaneously yielded better treatment responses than ipilimumab alone in patients with advanced melanoma who received no prior treatment...
Provectus Biopharmaceuticals, Inc., a clinical-stage oncology and dermatology biopharmaceutical company, enters phase 3 and has opened enrollment of patients for its phase 3 international FDA...
Melanoma cells become drug resistant by using surrounding healthy cells to provide a 'safe haven' from treatment, according to new research published in Cancer Cell.
In a study that included more than 32,000 cases of melanoma among Medicare patients, approximately 1 in 5 experienced a delay of surgery that was longer than 1.
In 1964, the US Surgeon General announced that smoking caused cancer and was not merely linked to it. It is now time to do the same with UV tanning, urge doctors.
A group of MIPT researchers together with their colleagues from Moscow, Nizhny Novgorod, Australia and the Netherlands have carried out the first systematic study analyzing the safety of so-called...
Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment, has announced study results demonstrating that its DecisionDx-Melanoma™ gene expression profile...
Results of a new study by UCLA researchers has found that a new triple combination drug therapy shows promising signs of more effectively controlling advanced melanoma than previous BRAF + MEK...
Melanoma patients whose tumors test positive for mutations in the NRAS gene were more likely to benefit from new immunotherapy drugs, according to a new study led by Vanderbilt-Ingram Cancer Center...